In a recent study published in JAMA Internal Medicine, researchers evaluated the ability of ChatGPT, an artificial intelligence-based chatbot assistant, to respond to patient questions posted on a publically accessible social media forum. Background:Owing to the quick expansion of digital health care, more and more patients have begun to raise queries on social media forums. Answering these questions is not just time-consuming but tedious for healthcare professionals. AI assistants, like ChatGPT, could help address this additional work and help draft quality responses, which later clinicians could review. read More
Author: Abhay Panchal
Olympus today announced it received FDA clearance for its new Evis X1 endoscopy system and two compatible gastrointestinal endoscopes. The FDA clearance covers Olympus’ GIF-1100 gastrointestinal videoscope indicated for use in the upper digestive tract, and the CF-HQ1100DL/I colonovideoscope indicated for use in the lower digestive tract. Olympus’s GI endoscopy systems are used by physicians to help diagnose, treat and observe diseases and disorders of the upper and lower GI tract, such as acid reflux, ulcers, Crohn’s disease, Celiac disease and colorectal cancer. According to the company, one of the most common uses of an endoscope is for screening colonoscopy,…
In one of the largest healthcare deals to date, Kaiser Permanente is acquiring Pennsylvania-based Geisinger Health and investing $5 billion to fold it into a new nonprofit subsidiary called Risant Health, which is set to purchase additional medical groups in coming years. While regulators still must review this initial acquisition, the marriage of Kaiser and Geisinger would create a behemoth with more than $100 billion in annual revenue — 95% of it coming from the Kaiser side of the equation. Like Kaiser, Geisinger both owns hospitals — 10 of them — and operates its own health insurance program. Unlike California-based…
This article reviews current bowel prep options, safety considerations, and best practice recommendations. Recommendations include additional fluids for low-volume preps, specific dosage timing, low-residue diet for part of the day prior to colonoscopy, use of online pharmacies and discount coupons to improve access to low-volume preps, and clinical support tools and navigation to improve compliance. Read More
MedicalResearch.com: What is the background for this study? Would you describe the ReCET procedure? Response: Currently more than 400 million people worldwide have type 2 diabetes (T2D) and these numbers are rapidly increasing. At the moment there is no treatment option available that effectively treats the root cause of T2D, i.e. insulin resistance, the increasing loss of response to our body’s own insulin. T2D is generally treated with drug therapy, yet drug therapy can be expensive, requires the patient to take their drugs every day, and at best “controls” the disease without actually resolving it. Despite the availability of many…
Nonalcoholic fatty liver disease (NAFLD) results from fat accumulation within the liver and ranges from simple steatosis to steatohepatitis progressing to cirrhosis. NAFLD has become the most common cause of liver disease in the United States and Europe because of an aging population and increased prevalence of metabolic syndrome characterized by hypertension, hyperlipidemia, type 2 diabetes (T2DM), and central obesity.1 NAFLD is strongly associated with obesity and T2DM, where the prevalence of NAFLD in patients undergoing bariatric surgery exceeds 90% compared with an estimated prevalence of 25% in the general population.2 In patients with NAFLD, the estimated prevalence rates of…
A liquid biopsy assay that tests for only six circulating tumor DNA (ctDNA) methylation markers has shown high accuracy in identifying the risk for relapse among patients with colorectal cancer (CRC). Patients who were ctDNA methylation positive 1 month after surgery were 17.5 times more likely to relapse, compared with ctDNA-negative patients. And following adjuvant chemotherapy, ctDNA-positive patients had a significantly shorter recurrence-free survival than their ctDNA-negative peers. Overall, “we found that ctDNA methylation was the most significant prognostic factor for recurrence-free survival among all clinicopathologic risk factors on multivariable analysis,” the authors, led by Shaobo Mo, MD, Fudan University…
CAMBRIDGE, Mass. & MINNEAPOLIS–(BUSINESS WIRE)–Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions and a wholly-owned operating company of Fortive Corporation (NYSE: FTV), announced today the upcoming commercial availability of SKOUT, real-time artificial intelligence for polyp detection, in the second quarter of 2023. SKOUT is indicated as a computer-aided detection tool to assist qualified and trained endoscopists in identifying potential colorectal polyps during colonoscopy examinations in adult patients undergoing colorectal cancer screening or surveillance. Colorectal cancer is the second leading cause of cancer-related deaths in…
Researchers Seek To Identify and Establish New Standards of Care PALO ALTO, CA / ACCESSWIRE / May 2, 2023 / Lynx.MD, a leading medical data intelligence platform, today announced a new partnership with Prometheus Laboratories Inc. (“Prometheus”) and Gastro Health to securely unite real-world clinical data for retrospective analysis of inflammatory bowel disease (IBD) biologic treatment. The partnership will bring together 10-years of de-identified IBD clinical laboratory data and patient data, using the Lynx Trusted Data Environment, to research and demonstrate the value of the Prometheus Anser® IFX therapeutic drug monitoring test to improve patient clinical outcomes and reduce overall…
CHICAGO, May 3, 2023 (Newswire.com) – Sifter SP, Inc. and Ayble Health, Inc. have entered a partnership to integrate Sifter’s innovative Shop By Diet technology and enhanced food and nutrition data into Ayble’s precision nutrition program. This partnership provides Ayble members an unprecedented level of dietary support for Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and other chronic digestive conditions. It’s all about diet personalization: one size fits none. Ayble’s HIPAA-compliant digital gastroenterology care platform, powered by Sifter technology, combines behavior science and clinical protocols to radically improve the standard of care for IBS/IBD patients. Read More